Figure 3.
PU.1 antisense transcript is activated in CBF leukemia patients. Transcript quantification of 3 patient cohorts for PU.1 antisense (asRNA, red) (A), mRNA (blue) (B), and asRNA/mRNA ratios (brown) (C) in t(8;21) AML (n = 18), inv(16) AML (n = 18), normal karyotype AML (NK-AML, n = 25), and healthy bone marrow samples. Promoter quantification for PU.1 AsPr (purple) (D), PrPr (steel blue) (E), and AsPr/PrPr (yellow) (F) ratio calculation in t(8;21) AML (n = 3), inv(16) AML (n = 2), and normal karyotype AML (NK-AML, n = 19) samples. (G) PU.1 asRNA/mRNA ratio expression relative to the French-American-British (FAB) classification for CBF-AML, NK-AML, and healthy CD34+ bone marrow samples from 2 patient cohorts (n = 55). Data are represented as mean ± standard error of the mean . *P < .05, ***P < .001, Wilcoxon and Student t tests.

PU.1 antisense transcript is activated in CBF leukemia patients. Transcript quantification of 3 patient cohorts for PU.1 antisense (asRNA, red) (A), mRNA (blue) (B), and asRNA/mRNA ratios (brown) (C) in t(8;21) AML (n = 18), inv(16) AML (n = 18), normal karyotype AML (NK-AML, n = 25), and healthy bone marrow samples. Promoter quantification for PU.1 AsPr (purple) (D), PrPr (steel blue) (E), and AsPr/PrPr (yellow) (F) ratio calculation in t(8;21) AML (n = 3), inv(16) AML (n = 2), and normal karyotype AML (NK-AML, n = 19) samples. (G) PU.1 asRNA/mRNA ratio expression relative to the French-American-British (FAB) classification for CBF-AML, NK-AML, and healthy CD34+ bone marrow samples from 2 patient cohorts (n = 55). Data are represented as mean ± standard error of the mean . *P < .05, ***P < .001, Wilcoxon and Student t tests.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal